60 Degrees Pharmaceuticals Posts 65% Revenue Growth Amid Rising Costs
Event summary
- FY 2025 net product revenues increased 65% to $1.0 million, driven by rising sales and price increases.
- Gross profit remained stable at approximately $223.8 thousand despite inventory write-offs.
- Operating expenses decreased to $8.4 million from $10.0 million in 2024, primarily due to lower R&D costs.
- Net loss attributable to common shareholders improved to $7.37 million, or $11.73 per share, from $7.96 million in 2024.
- Company raised $4 million through an ATM facility, exhausting current shelf capacity.
The big picture
60 Degrees Pharmaceuticals' revenue growth reflects its expanding market reach and pricing power, but rising selling expenses and the need for further funding highlight the challenges of scaling operations. The company's strategic focus on vector-borne diseases positions it within a growing sector, but its ability to sustain profitability and secure additional financing will be key to long-term success.
What we're watching
- Clinical Data Release
- The timing and results of the interim analysis of the randomized hospital study for babesiosis treatment could significantly impact the company's strategic direction.
- Sales Expansion
- The impact of partnerships with GoodRx and Runway Health on ARAKODA's market penetration and revenue growth will be critical to monitor.
- Regulatory Progress
- The pace at which the company advances the regulatory process for Australian Chestnut Extract as a non-prescription botanical product will determine its commercial viability.
Related topics